Semaglutide cut the risk of kidney failure and cardiovascular death by 24% in patients with T2D and chronic kidney disease. Nephrologists didn't expect results this large. Here's what the FLOW trial means for CKD patients in March 2026.
Key Result: The FLOW trial — the first kidney outcome trial for a GLP-1 receptor agonist — showed semaglutide 1mg reduced the composite of kidney failure, ≥50% eGFR decline, kidney death, or cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease, versus placebo. All-cause mortality was also reduced. The FDA has since approved semaglutide for reducing the risk of kidney disease progression and cardiovascular death in adults with T2D and CKD — a landmark new indication.
Chronic kidney disease (CKD) affects approximately 37 million Americans — 15% of the adult population. It is strongly associated with type 2 diabetes (the leading cause of CKD) and hypertension (the second). CKD is defined by persistent reduction in kidney function (estimated glomerular filtration rate, eGFR <60 mL/min/1.73m²) or markers of kidney damage including proteinuria for more than 3 months.
CKD progression to end-stage renal disease (ESRD) requiring dialysis or transplant is catastrophic for quality of life and carries a 5-year mortality rate that rivals many cancers. Even moderate CKD substantially increases cardiovascular risk — patients with T2D and CKD have cardiovascular event rates two to three times higher than T2D patients with normal kidney function.
Until recently, the pharmacological armamentarium for CKD was limited: blood pressure control (ACE inhibitors, ARBs), blood sugar control, and since 2019, SGLT2 inhibitors (which demonstrated CKD progression reduction in the CREDENCE and DAPA-CKD trials). GLP-1 receptor agonists had promising mechanistic data in preclinical models but lacked a dedicated kidney outcome trial — until FLOW.
FLOW enrolled 3,533 adults with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73m², with proteinuria indicating kidney damage). Participants received once-weekly subcutaneous semaglutide 1mg or placebo. Most participants were already on ACE inhibitors or ARBs (standard of care), and approximately 16% were on SGLT2 inhibitors at baseline.
Primary composite endpoint — sustained kidney failure, ≥50% decline in eGFR, kidney disease death, or cardiovascular death:
Secondary kidney endpoints were consistently positive: eGFR slope improvement (semaglutide slowed kidney function decline), proteinuria reduction, and all-cause mortality (HR 0.80, a 20% mortality reduction that approached statistical significance). Cardiovascular death was numerically reduced consistent with the SELECT trial data.
The FLOW trial was terminated early by the independent data monitoring committee — a decision that occurs only when interim evidence of benefit is so compelling that continuing the placebo arm would be unethical. Early termination typically means the final effect size was even more robust than the published result.
The surprise was not that semaglutide showed kidney benefit — that was anticipated from mechanistic data and the CREDENCE precedent with SGLT2 inhibitors. The surprise was the magnitude and the breadth of the benefit in a population that was already on maximum background therapy (ACE inhibitors/ARBs), which represent the established standard for CKD protection.
Adding semaglutide on top of already-optimized background therapy — and achieving a 24% further reduction in the primary endpoint — indicates a distinct and additive mechanism of kidney protection beyond what blood pressure control and RAAS blockade alone provide. This positions semaglutide as a genuine third pillar of CKD pharmacotherapy (alongside RAAS blockers and SGLT2 inhibitors) in T2D patients.
GLP-1 receptors are expressed in multiple kidney cell types, and semaglutide's kidney protection appears to operate through several pathways:
Semaglutide is now FDA-approved for CKD + T2D. Talk to a licensed physician about whether compounded semaglutide is appropriate for your situation.
The FLOW trial enrolled patients mostly already on RAAS blockers, and approximately 16% on SGLT2 inhibitors. Semaglutide produced benefit on top of both. This has led nephrology thought leaders to advocate for a triple-therapy approach for T2D patients with CKD and high proteinuria: ACE inhibitor or ARB + SGLT2 inhibitor + GLP-1 receptor agonist.
Each component addresses different mechanisms: RAAS blockade lowers intraglomerular pressure and reduces proteinuria via hemodynamic effects; SGLT2 inhibitors reduce tubuloglomerular feedback, lower intraglomerular pressure, and have direct anti-inflammatory tubular effects; GLP-1 receptor agonists add anti-inflammatory, anti-fibrotic, metabolic, and cardiovascular benefits. The mechanisms are genuinely complementary and potentially synergistic.
Whether the combination should be implemented simultaneously or sequentially, and the optimal sequencing, is under active study. The practical guidance from major nephrology societies: maximize tolerated doses of RAAS blockers, add an SGLT2 inhibitor if tolerated and indicated, and consider adding a GLP-1 receptor agonist for additional cardiorenal protection — particularly in patients with proteinuria, cardiovascular risk, and/or poor glycemic control.
Important nuances for patients with CKD considering GLP-1 therapy:
Care Bare Rx's physician-supervised approach ensures your GLP-1 therapy is integrated with your existing kidney health management.
Get Started with Care Bare Rx →Claims sourced from the FLOW trial (NEJM 2024), FDA approval documents, and KDIGO/ASN guideline updates. No Fluff. Just Sources.
CKD-aware physician programs